- CEO
- S. M. Saifur Rahman
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Nov 22, 2010
- Business
- Active Fine Chemicals Limited is a Bangladesh-based chemical and pharmaceutical manufacturing company that specializes in the production, marketing, and distribution of active pharmaceutical ingredients (APIs) and laboratory-grade chemical reagents. Founded in 2004 and headquartered in Dhaka, Bangladesh, the company operates a multi-purpose manufacturing facility located in Munshiganj and caters primarily to domestic pharmaceutical formulation manufacturers while exporting bulk chemical agents to international markets in Asia and Africa. The company offers products across various therapeutic segments and chemical categories, including macrolide and broad-spectrum antibiotics, such as azithromycin dihydrate, erythromycin ethyl succinate, erythromycin stearate, ciprofloxacin hydrochloride, cefixime trihydrate, and cefuroxime axetil; anti-ulcerants, such as esomeprazole magnesium trihydrate, esomeprazole pellets, and pantoprazole sodium sesquihydrate; anti-diabetic agents, such as metformin hydrochloride, sitagliptin phosphate monohydrate, vildagliptin, linagliptin, gliclazide, and glimepiride; cardiovascular and lipid-lowering compounds, such as atorvastatin, rosuvastatin calcium, losartan potassium, amlodipine besylate, and ticagrelor; pain management and central nervous system drugs, such as pregabalin, venlafaxine hydrochloride, paracetamol, etoricoxib, and ketorolac tromethamine; anti-histamines, such as cetirizine, fexofenadine hydrochloride, desloratadine, and ebastine; anti-fungals, including fluconazole; and customized analytical laboratory solvents and high-purity powder reagents. In recent developments, Active Fine Chemicals Limited has faced major operational disruptions and corporate restructuring, marked by the complete suspension of manufacturing activities at its Munshiganj plant, stock reclassification to the Z category on the Dhaka Stock Exchange, and comprehensive regulatory investigations initiated by the Bangladesh Securities and Exchange Commission concerning financial reporting disclosures, sponsor-director equity compliance, and operational governance.